The Use of Ondansetron for the Treatment of Nausea in Dogs With Vestibular Syndrome

S. Foth
University of Veterinary Medicine Hannover

S. Meller
University of Veterinary Medicine Hannover

H. Kenward
Royal Veterinary College

J. Elliot
Royal Veterinary College

L. Pelligand
Royal Veterinary College

H. A. Volk
University of Veterinary Medicine Hannover

Research Article

Keywords: Vestibular syndrome, Ondansetron, Nausea, Behavioural Assessment

DOI: https://doi.org/10.21203/rs.3.rs-279349/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background: Vestibular syndrome is often accompanied by nausea. Drugs currently approved for its treatment have been developed to stop vomiting but not nausea. The efficacy of 5-HT₃ receptor antagonists to reduce nausea has been described for chemotherapy, but not for nausea secondary to vestibular disorders.

Methods: Sixteen dogs with vestibular syndrome-associated nausea were included in the open-label, multicentric study. The intensity of nausea-like behaviour was analysed before ondansetron administration (0.5 mg/kg i.v.) and 2 h afterwards, using a validated 5-point-scale. The occurrence and frequency of salivation, lip licking, restlessness, vocalisation, lethargy, and vomiting were assessed.

Results: All dogs initially showed signs of nausea, whereas only 31% showed vomitus. The intensity of nausea was significantly reduced in all dogs (p≤0.0001) 2 h after ondansetron administration, including the clinical signs of nausea analysed in 11 dogs (salivation [p=0.0078], lip licking [p=0.0078], restlessness [p=0.0039], and lethargy [p=0.0078]) except for vocalisation (p>0.9999).

Conclusion: The results provide preliminary evidence of the potential benefit of ondansetron in the treatment of nausea, which was present in all examined dogs. Vomiting was only observed in 5 dogs indicating that nausea can occur separately and should not be perceived only as a preceding stimulation of the vomiting centre.

Background

Dogs with dysfunctions of the vestibular system are frequently encountered in primary veterinary care,¹ with an overall prevalence of 0.08% in primary care and an even higher prevalence of 0.36% in dogs aged 9 years or older.² Dysfunctions of the vestibular system do manifest in various neurological clinical signs, such as head tilt, nystagmus, or ataxia.³,⁴ Additionally, signs of kinetosis (motion sickness) can also occur due to the fact that the nucleus of the solitary tract, which is responsible for nausea and emesis, receives vestibular input.⁵ Thompson et al. (2009) pointed out that various common central and peripheral vestibular diseases in humans (e.g., peripheral and central vestibular syndrome, Meniere's syndrome, vestibular neuritis, labyrinthitis and vestibular migraine) are associated with symptoms of nausea and vomiting and require intervention with anti-nausea medication.⁶ Due to similar pathways in the central nervous system in both species, it can be assumed that dogs perceive nausea as individually and diversely as human patients do.⁷,⁸ Nausea is a complex and multi-dimensional sensation. It is not only affected by vestibular inputs but also by many other factors like somatic stress, stimuli from the gastrointestinal tract, and by physical and psychological factors.⁹

The sensation of nausea has a protective function and is often associated with the urge to vomit. However, nausea is not implicitly associated with the result of vomiting. Nausea can be perceived in different intensities and be associated with a preceding stimulation of the vomiting centre, which leads to vomiting only at higher intensity. Nevertheless, the incorrect assumption that dogs without vomiting are consistently not nauseous is omnipresent in veterinary practise. Nausea is pharmacologically much more difficult to control than vomiting. This is why Horn et al. (2007) assumed that the neurobiological systems that cause vomiting and nausea are at least partially separated.¹⁰

The currently approved medication in veterinary medicine for the treatment of nausea and vomiting in cats and dogs – e.g. maropitant (neurokinin-1-receptor antagonist) and metoclopramide (dopamine 2-receptor antagonist) – successfully limits vomiting. Yet dogs and other animals still show clinical signs of nausea after their use. Studies confirm that maropitant and metoclopramide do not have a clinically relevant effect against nausea compared to placebo.¹¹–₂⁰

Interestingly, 5-HT₃ receptor antagonists, such as ondansetron, can eliminate both nausea and vomiting.²¹,²² Ondansetron is a selective 5-HT₃ receptor antagonist, whose central effect may be explained by the high distribution rate of 5-HT₃ receptors in the area postrema, which is associated with the nucleus of the solitary tract and by the pivotal role of the central serotonergic (5-HT) system for both nausea and vomiting.²¹,²² Furthermore, a large proportion of 5-HT₃ receptors was detected in the periphery (vagal nerve, enteric neuronal elements of the gastrointestinal tract), whose activation, accompanied by an increase of vasopressin levels, culminates in gastric dysrhythmias.²¹,²³ Ondansetron has already been proven as a successful treatment of chemotherapy-related nausea and vomiting in both human and animals, and showed clear advantages over antidopaminergic drugs (e.g. metoclopramide), antihistamines, neurokinin-1-receptor antagonists (e.g. maropitant) and anticholinergics.²⁴ Similar results have been documented in experiments with ferrets²⁵ and further experiments have shown ondansetron being superior to other antiemetics in cases of nausea due to reasons other than a vestibular disturbance.¹³,¹⁵,²³,²⁶

In general, the clinical efficacy assessment of anti-nausea drugs is difficult.²⁷ Detecting and grading the subjective status of nausea is a requirement in drug development. Evaluating nausea is strongly linked to precise observations of facial expressions and behaviour. Typical pathophysiological and behavioural patterns such as salivation, licking lips, restlessness, lethargy and vocalisation can be witnessed.¹⁷ The appearance of these prodromal signs and autonomic responses has a higher probability by a rising intensity of nausea.²⁸ Due to the lack of communication capabilities, the detection of nausea in dogs is even more complicated compared to humans. Furthermore, dogs may mask signs during their visit to the clinic because of stress and discomfort, so that symptoms are even more subtle. A numerical rating scale (NRS) established by Rau et al. (2010)¹⁷ and further developed by Kenward et al. (2015)²⁹, which evaluates the general nausea and the prodromal signs on a 5-point-scale, supports precise and conscious behavioural assessment. The NRS acts as an additional tool for observers to reliably detect even mild clinical signs of nausea.

Studies addressing the issue of treatment and assessment of nausea due to vestibular disorders have not yet been published to the authors’ knowledge. Veterinary experience has been limited to studying nausea and vomiting induced by chemotherapeutic and other drugs.¹²,¹³,¹₈,₂₀,₂₅ Therefore, the aim of this case series is to describe the clinical experience of treatment of nausea resulting from vestibular syndrome in dogs with ondansetron, a 5-HT₃ receptor antagonist, evaluated by behavioural assessment using a formerly validated NRS.²⁹
Results

Signalment

Sixteen dogs were included in the study (Golden Retriever \(n = 4\), mix breeds \(n = 2\), and one of each of the following breeds Australian Shepherd, Beagle, Boxer, Chihuahua, Cocker Spaniel, French Bulldog, Irish Soft coated Wheaten Terrier, Lurcher, Malinois and Yorkshire Terrier). Medical records containing age, breed, diagnosis, premedication, previous history of vestibular syndrome and observed events of vomiting are summarised in additional Table 1.

Median age at onset of neurological deficits was 115 months (interquartile range [IQR]: 68–159 months). Ten dogs (62.5%) had no clinical signs of central involvement and symptoms were limited to the peripheral vestibular system. The majority of these dogs (7/10) showed characteristics of idiopathic vestibular syndrome, two of ten dogs were diagnosed with otitis media and interna on the affected side, and one dog showed signs of an iatrogenic peripheral vestibular syndrome after an extirpation of a trichoplastoma via bullaosteotomy. Six dogs (37.5%) showed signs consistent with central vestibular syndrome. In three out of six cases the magnetic resonance imaging (MRI) in combination with cerebrospinal fluid analysis was suggestive of neoplastic or inflammatory conditions (1 one dog with neoplasia, two dogs with a presumed necrotizing meningoencephalitis), whereas for the remaining three dogs no further diagnostic measures were conducted.

All dogs included in the study exhibited signs of nausea. A total of five dogs (31.3%) showed vomitus prior to the study. The severity of nausea in dogs with vs. without vomitus (T0) was not statistically significant \((p = 0.6223)\). The improvement of nausea scores in dogs with vs. without vomitus after ondansetron administration was not statistically different \((p = 0.8587)\). In the neurological examination, 14 dogs (87.5%) had head tilt and nystagmus. Ataxia was observed in 13 dogs (81.3%). All six dogs diagnosed with central vestibular syndrome demonstrated cranial nerve deficits, decreased mentation and, in all but one dog, proprioceptive deficits (Table 1).

| Neurological sign             | Number of dogs |
|-------------------------------|----------------|
| Head tilt                     | 14             |
| Nystagmus                     | 14             |
| Ataxia                        | 13             |
| Cranial nerve deficits        | 6              |
| Collapse                      | 5              |
| Proprioceptive deficits       | 5              |
| Strabismus                    | 5              |
| Deficits in postural reactions| 4              |

Behavioural Assessment

The overall severity of nausea was significantly decreased from a pre-treatment median score of 5.0 (IQR: 2.0–5.0) to post-treatment median score of 1.0 (IQR: 0–4.0, \(p \leq 0.0001\), Fig. 1). A reduction in the general nausea score was observed in all 16 dogs. The detailed assessment of each clinical sign suggestive of nausea-like behaviour \((n = 11)\) revealed significant reduction in their scores from T0 to T2 for salivation \((p = 0.0078)\), lip licking \((p = 0.0078)\), restlessness \((p = 0.0039)\), and lethargy \((p = 0.0078)\) but not for vocalisation \((p = 0.9999\), Fig. 2). Vocalisation was only observed in one dog as an expression of discomfort and nausea.

Discussion

The objective of this study was to evaluate the anti-nausea efficacy of ondansetron, a 5HT\(_3\) receptor antagonist, in dogs with vestibular disease. In the current open-label prospective multicentre study in 16 dogs with vestibular disease, the degree of nausea and clinical signs suggestive of nausea-like behaviour were significantly reduced after ondansetron administration. Around a third of the patients in this study also showed vomiting in addition to nausea, which also did stop after ondansetron was given. Despite the limitations of an open-label prospective study, this study provides the first evidence of the potential benefit of ondansetron in the treatment of nausea induced by vestibular syndrome and highlights the importance of assessing the degree of nausea in these neurological patients.

In veterinary care, there is a need for a better awareness of veterinary surgeons for the difference between a drug’s antiemetic and/or antinausea effect. Nausea is relatively easy to measure in people, as they can report the severity of nausea they are experiencing. In dogs, however, behaviour and facial expression must be observed precisely in order to adequately evaluate their level of nausea.\(^{5,29}\) Vomiting is often seen and described in vestibular disorders,\(^{31}\) however, the prevalence of preceding nausea has not been described. Radulescu et al. (2020) and Schunk et al. (1988) described a prevalence of vomiting of 25.7% and 40%, respectively.\(^{5,32}\) This is consistent with our results showing an overall prevalence of vomiting in 31.3% of dogs. Nevertheless, all dogs in our study showed clinical signs and behaviour suggestive of nausea. This supports reports that nausea and vomiting can occur separately and that it should not
be assumed that a dog that is not vomiting cannot be nauseous. Studies of maropitant, an antiemetic drug developed for the use in veterinary medicine, described the cessation of vomiting but still measurable signs of nausea.\textsuperscript{11–18} For some owners or veterinarians the absence of vomiting might be an acceptable and satisfying treatment outcome. However, human patients being treated with chemotherapeutics usually consider nausea control more important than emesis control.\textsuperscript{31,34} Furthermore, one could assume when nausea leads to vomiting, there is temporary relief of the nausea sensation, but blocking vomiting without relieving the nausea may be burdensome. This highlights the importance of nausea research in veterinary patients. Kraus et al. (2019) also determined that many canine owners are aware of the discomfort and negative influence of nausea on animal welfare and would accept higher costs and longer hospital stays in return for an effective relief for their pets.\textsuperscript{35}

Golden Retriever (n = 4) and mixed-breed dogs (n = 2) were most likely to have a diagnosis of ‘vestibular syndrome’ in this case series. Bongartz et al. (2020) also found mixed-breed dogs (15.1%) to be the most likely affected.\textsuperscript{36} Similar breeds were mentioned by some recently published studies consistent with our findings.\textsuperscript{2,3,28} In the present study, the median age at onset of neurological deficits was 115 months (9.58 years). Median age reported recently elsewhere ranged from 6.8 years to 12.68 years.\textsuperscript{23,28–40} This apparently wide range in age could represent the different study inclusion criteria. Idiopathic vestibular syndrome tends to appear more frequently in older dogs in contrast to meningoencephalitis of unknown origin, which is a frequent cause of central vestibular syndrome. It mainly affects female brachycephalic dog breeds younger than 5.5 years.\textsuperscript{40} Neurological examination is a very accurate clinical tool to determine the presumed neuroanatomical localisation of neurological diseases within the vestibular system in more than 90% of cases, according to Bongartz et al. (2020).\textsuperscript{36} The main clinical findings recorded in the neurological examination of the 16 dogs were head tilt and nystagmus, followed by ataxia. These signs are the most frequently observed clinical findings consistent with vestibular syndrome.\textsuperscript{2,3,28,37,41} In summary, although the sample size in this case series was small, the cases included appear to be representative for the commonly affected canine population by vestibular syndrome.

The pathogenesis of nausea is complex.\textsuperscript{9,10,21,22,27,42} It is not completely understood and includes central and peripheral stimuli. Initiating stimuli originate from the cerebral cortex and limbic system but also from gastric dysrhythmias, the vestibular system, the cerebellum and the area postrema. The stimuli terminate in the nucleus tractus solitarius (NTS) which is located in the brainstem and forms the dorsal vagal complex, together with the area postrema and the dorsal motor nucleus of the vagus. The NTS integrates stimuli of the afferent neurons, which are mediated by serotonin/dopamine, histamine/acylcholine in combination with serotonin/dopamine and substance \textsuperscript{p}.\textsuperscript{21,122} Stern et al. (2011) hypothesised that the brainstem is not involved in the genesis of nausea but is required for the prodromal signs (salivation, lip licking, restlessness, lethargy, vocalisation, emesis). Therefore, the pathway of vomiting and nausea can be assumed from this point on separated.\textsuperscript{42} For the induction of the sensation nausea and the associated increased release of arginine vasopressin (AVP)\textsuperscript{8,9,42–45}, ‘higher’ regions of the brain are required, while for vomitus the functions of the brainstem as the ‘vomiting centre’ are sufficient.\textsuperscript{42} Projections from the rostral NTS target ‘higher brain areas’ like the hypothalamus via the lateral parabrachial nucleus, in order to initiate the release of AVP from the posterior pituitary. Another hypothalamic effect is the reduction of food intake and the modulation of autonomic outflow via activation of the sympathetic system leading to an increase in epinephrine and serotonin (5-HT) followed by vasoconstriction. Other ‘higher’ brain areas activated by the NTS probably lead to the conscious awareness of the sensation nausea.\textsuperscript{42}

The vestibular system influences not only the cerebellum, spinal cord and extraocular muscles but also the cranial nerve III and the vestibular nuclei as direct pathways, which could induce nausea. By activation of projections to the dorsal vagal complex and ascending projections to higher brain areas like thalamus, lateral postcentral gyrus, insular cortex and temporoparietal cortex the induction of nausea can be modulated. The complexity and multidimensional nature of nausea makes the pharmacological management challenging.\textsuperscript{34}

The 5-HT\textsubscript{3} receptors form serotonin-gated ion channels that interact with further 5-HT-receptor subtypes as well as with other neurotransmitters.\textsuperscript{44} They have a wide distribution and range of function in the central and peripheral nervous system.\textsuperscript{46} Neurons expressing immunoreactivity for the 5-HT\textsubscript{3} receptor subtypes are located in the forebrain, brainstem (especially trigeminal motor and facial nuclei) as well as in the spinal cord.\textsuperscript{47} In addition to other regions in the central nervous system, the distribution of 5-HT\textsubscript{3} receptors in the area postrema (the chemoreceptor trigger zone), limbic and cortical regions,\textsuperscript{48} and the NTS (especially the rostral part, which interacts with higher brain regions\textsuperscript{42}) is particularly important with regard to pharmacological antinausea intervention.\textsuperscript{49–53} Balaban et al. (2014) examined neuronal activation after galvanic vestibular stimulation in cats with the help of the detection of c-Fos expression.\textsuperscript{28} They concluded two networks being positively correlated with the severity of motion sickness signs. The networks include medial, lateral, superior and inferior vestibular nuclei, the lateral nuclei of the NTS, parabrachial nucleus and in general serotonergic and non-serotonergic projections.

Miller et al. (1996) found a region in the human inferior frontal gyrus activated via head movement during yaw-axis rotation in the matter of number of dipoles related to the intensity of nausea.\textsuperscript{54} The same region was detected in functional MRI after galvanic vestibular stimulation or caloric testing. This specific region was only activated through motion sickness associated nausea and not via speech or finger movement, which are the normal activating stimuli of this region. The same region was also activated after the ingestion of the syrup of ipecac, a well-known herbal substance that induces nausea and vomiting. After ondansetron was applied, the intensity of dipoles in this region was significantly reduced.\textsuperscript{42,54} Components of the vestibular system, representing one possible origin of nausea stimuli, have a widespread distribution of 5-HT-receptors. These regions of receptor accumulation serve as possible anchor points in the axis of nausea-induction to be targeted pharmacologically. The serotonin receptor antagonist ondansetron induces a greater antinausea effect than maropitant or metoclopramide. Neurokinin-1-receptor and dopamine-2-receptor are represented within the brain, but not being involved in the release of AVP for example.\textsuperscript{55,56}

Nausea is a subjective condition and its presence and magnitude are difficult to assess in both animals and humans, as there still is a lack of a direct measurement method until today. In humans we have to rely on self-reports while in animals we have to rely on a person’s interpretation of the observed behaviour. In human medicine, there are several types of validated scales including visual analogue scales (VAS) and numerical rating scales (NRS) in terms of self-reporting.\textsuperscript{57,58} Although comparing a subjective sensation between several individuals remains challenging, the recognition of nausea in humans itself is much easier than in animals. Therefore, the first step to improve the welfare of canine patients suffering from nausea is to simplify and to improve the
recognition of the condition in the first place. Therefore valid methods for measurement are needed. Kenward et al. (2015) refer in their publication to pain as an analogy to nausea and compare the concept of nociception with 'nausiception'.

Both, nausea and pain, are subjective sensations which require a conscious perception of the individual and serve as a protective function. These parallels allow access to pain rating scales as possible approach to evaluate nausea, as there are no validated scores for nausea in animals. Pain has been often measured by means of simple descriptive scale (SDS), NRS or VAS with only focus on intensity. Holton et al. (1998) and Downie et al. (1978) concluded that the NRS, which is extensively used in human medicine, represents a reliable compromise between a SDS with a lower level of sensitivity as well as the VAS and its more complicated use.

The used NRS in the present study is a modified version of the one established by Rau et al. (2010) and further validated by Kenward et al (2015). In this case series, we have chosen scale descriptions relying on typical prodromal signs of nausea, which offers the possibility of making a statement about the dogs' overall level of nausea. In addition to assessment of nauseaevoke behaviour patterns, the used scale also included evaluation of dog-human- interactions by evaluating lethargy and, therefore, the dogs' reaction to external stimuli. In general, the scale descriptions facilitated and standardised evaluation although it is less sensitive than the VAS from de la Puente et al. (2007) as the scores are limited to the descriptions on scale and does not allow ratings in between. Nevertheless, in order to minimize inconsistencies in interpretation, every dog was assessed by the same trained observer at time points before (T0) and 2 h after (T2) ondansetron administration. Both observers at the RVC and the TiHo found a decrease in nausea-like-behaviour after ondansetron administration. The NRS with the given gradations helped to achieve a higher level of objectivity, comparability and reproducibility in this case series.

Some limitations of the present study should be noted. No blinding of observers was performed and the analyses took place at two different test centres. The observed patients in this cases series were part of a diseased population of elderly dogs (median age of onset 115 months) with a variety of different breeds and potentially long medical history with interfering pre-existing illnesses. These dogs were exposed to a stressful environment (hospital), where they were handled by unfamiliar people. Stress will certainly have been reflected in the dogs' behaviour and thus may have influenced the behavioural assessment. Efforts were made in the study design to try to reduce the effect of stress by giving dogs a period of 1 h of acclimatisation. In addition to the small sample size, the absence of an untreated control group must be taken into account. As the intensity of the signs of nausea may decrease over time due to the patient's habitation to the state of vestibular disorder, resulting in clinical improvement. As nausea varies greatly between individuals, only a placebo-controlled cross-over study can correctly compare the state of nausea in each individual. Individual adaptation to vestibular disorders is difficult to assess in clinical trials; only observation extending beyond the actual study period and effective plasma concentration can lead to preliminary evidence. However, the paired comparisons conducted between individuals showed an overall significant decrease of nausea scores in the participating dogs with every dog experiencing an improvement in the scores after ondansetron treatment.

**Conclusion**

This is the first study to provide evidence of the efficacy of ondansetron as a treatment for nausea in dogs with vestibular disease. Better control of nausea will have a major impact on this patient population, as there is currently no adequate relief of nausea in veterinary medicine. Considering the limitations of this study, a placebo controlled, double-blind, randomized cross-over study is currently under way to confirm the study results. Inclusion of the measurement of a possible objective biomarker of nausea, like arginine vasopressin, in future studies would enhance not only the interpretation of the results but also the detection of an underreported clinical sign and therefore improve canine welfare in veterinary medicine and side effect profiling in laboratory canines.

**Material And Methods**

**Patients & inclusion criteria**

Dogs were presented to the neurology and neurosurgery service at the Department of Small Animal Medicine & Surgery, University of Veterinary Medicine Hannover (TiHo), between October 2019 and March 2020 (n = 11) and at the Queen Mother Hospital for Animals, Royal Veterinary College (RVC), between January and August 2014 (n = 5). The client-owned dogs met the inclusion criteria if they showed clinical signs consistent with peripheral or central vestibular syndrome and nausea at the day of presentation. Owners gave informed written consent to diagnostic procedures and treatment. Medical records containing age, breed, diagnosis, premedication, previous history of vestibular syndrome, and observed events of vomiting were evaluated. Dogs presented at the RVC were given a 24 h-wash out period before they received an antiemetic drug prior to ondansetron administration in order to avoid drug interference. At the TiHo wash out periods of 15 h after maropitant (plasma concentration half-life $t_{1/2}$ 5.62 ± 0.77 h, post i.v.13) and 13 h after metoclopramide ($t_{1/2}$ = 0.87 ± 0.17 h, post i.v.13) administration were provided prior to ondansetron administration. Furthermore, treatment sheets were reviewed prior to the study to avoid concomitant or prior administration of drugs with potential antinausea effects. Animal procedures undertaken were approved by the RVC's Ethics and Welfare Committee in relation to the UK Home Office Animals (Scientific Procedures) Act 1986 (ASPA) project license 70/7269.

**Study protocol**

After hospitalisation, a period of at least 1 h was provided to let the dogs acclimatise to the ward. Venous access was established and all dogs were treated with fluid therapy intravenously at a maintenance dose of 2 ml/kg/h (Fig. 3). The first behavioural assessment was performed at time point T0 immediately before administration of the drug ondansetron (Cellondan®, STADAPHARM GmbH, Germany, or Zofran®, GlaxoSmithkline, UK) at a single dose of 0.5 mg/kg i.v. by the attending clinician. The ondansetron dosage used during the study corresponds to the antiemetic dose recommended by the BSAVA Small Animal Formulary. Prior to application with slow flow rates, the medication was diluted 1:1 with 0.9% saline in order to reduce the risk of phlebitis. 2 h after injection (T2), behaviour was evaluated again by the same observer.
Behavioural Assessments/Nausea-Score

A numerical rating scale (NRS) adapted from the 5 point-scale established by Rau et al. (2010) and further developed by Kenward et al. (2015) was used. One trained observer at the RVC and another at the TiHo conducted the observations in a non-blinded fashion before and after administering the drug. An assessment of general nausealike behaviour was made on the 5-point scale, where 0 = no nausea and 5 = severe nausea, depending on the appearance and frequency of signs including salivation, lip licking, restlessness, vocalisation and lethargy. A detailed assessment of each of these five prodromal clinical signs interpreted and suggestive for nausea-like behaviour was conducted for the eleven dogs, which presented at the TiHo (Table 2). The number of vomits was recorded for all dogs prior and during the study.

Table 2
Numerical rating scale (NRS). NRS scoring was used for behavioural nausea assessment at time-points T0 and T2.

| Score value | General Nausea | Salivation | Lip Licking | Vocalisation | Restlessness | Lethargy |
|-------------|----------------|------------|-------------|--------------|--------------|----------|
| 0 (None)    | No nausea      | Slight dampness around the mouth | None | None | None | None |
| 1 (Mild)    | Short period of mild nausea | Wet around the muzzle | Occasional lip licking | Occasional short whining | E.g. occasional panting/tuming/circling/digging | Sleeping, responsive to stimuli |
| 2 (Mild/Moderate) | Longer period of mild nausea or short period of moderate | Pools of saliva around the lips | Frequent lip licking | Occasional whining | E.g. shows longer panting/tuming/circling/digging behaviour, but calms down after a short time | Sleeping, responsive to repeated stimuli |
| 3 (Moderate) | Short period of moderate nausea or short period of severe nausea | Dripping saliva | Constant lip licking for periods up to a few minutes | Frequent whining | E.g. anxious, repeated panting/tuming/circling/digging | Sleeping for long periods, responsive to stimuli |
| 4 (Moderate/Severe) | Longer period of severe nausea | | Frequent lip licking for period up to several minutes | Constant whining or crying for periods of a few minutes | E.g. restless panting/tuming/circling/digging behaviour, only very short cal | Sleeping for long periods, responsive to repeated stimuli |

Statistical Analysis

All statistical analyses were performed using GraphPad Prism 9 (GraphPad Software, Inc., La Jolla, CA, USA) in order to evaluate for differences in nausea-like behaviour (general nausea) and each of the individual signs suggestive for nausea before and after the administration of ondansetron and between dogs with and without vomiting. Data were analysed by either the Wilcoxon signed rank test or Mann Whitney U Test, where appropriate. Data are presented as median and interquartile range. Tests were two-tailed and \( p \leq 0.05 \) was regarded statistically significant.

Declarations

Ethics approval and consent to participate

Animal procedures undertaken were approved by the RVC’s Ethics and Welfare Committee in relation to the UK Home Office Animals (Scientific Procedures) Act 1986 (ASPA) project license 70/7269.

Consent for publication

Not applicable

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Competing interests

The authors declare no conflicts of interest.

Funding

The study was funded by the GKF - Gesellschaft zur Förderung Kynologischer Forschung e.V.. The funding body played no role in the design, analysis and reporting of the study.

Author’s contributions
SF participated in the planning of the study, carried out the main practical work, patient recruitment, data analyses and drafted the manuscript. SM participated in the planning of the study, drafted the manuscript and was responsible for data analyses. HV and LP designed the study. HV supervised and coordinated the research, drafted the manuscript and was responsible for data analyses. HK acquired the data from the RVC. HK, LP und JE also participated in drafting the manuscript.

Acknowledgements

The authors would like to express gratitude to the GKF - Gesellschaft zur Förderung Kynologischer Forschung e.V. for the financial support and the team at neurology service at the Department of Small Animal Medicine & Surgery, University of Veterinary Medicine Hannover (TiHo) for their help and assistance during the data collection.

References

1. Kraeling M. Proposed Treatment for Geriatric Vestibular Disease in Dogs. *Top Companion Anim Med*. 2014 Mar;29(1):6–9.
2. Radulescu SM, Humm K, Eramanis LM, Volk HA, Church DB, Brodbelt D, et al. Vestibular disease in dogs under UK primary veterinary care: Epidemiology and clinical management. *J Vet Intern Med*. 2020 Sep;10;34(5):1993–2004.
3. Rossmeisl JH. Vestibular Disease in Dogs and Cats. *Vet Clin North Am Small Anim Pract*. 2010 Jan;40(1):81–100.
4. Kent M, Platt SR, Schatzberg SJ. The neurology of balance: Function and dysfunction of the vestibular system in dogs and cats. *Vet J*. 2010 Sep;185(3):247–58.
5. Yates BJ, Grelot L, Kerman IA, Balaban CD, Jakus J, Miller AD. Organization of vestibular inputs to nucleus tractus solitarius and adjacent structures in cat brain stem. *Am J Physiol Integr Comp Physiol*. 1994 Oct 1;267(4):R974–83.
6. Thompson TL, Amedee R. Vertigo: a review of common peripheral and central vestibular disorders. *Ochsner J*. 2009;9(1):20–6.
7. Andrews PLR, Sanger GJ. Nausea and the quest for the perfect anti-emetic. *Eur J Pharmacol*. 2014 Jan,722(1):108–21.
8. Kenward H, Pelligand L, Savary-Bataille K, Elliott J. Nausea: Current knowledge of mechanisms, measurement and clinical impact. *Vet J*. 2015 Jan;203(1):36–43.
9. Koch KL. A noxious trio: nausea, gastric dysrhythmias and vasopressin. *Neurogastroenterol Motil*. 1997 Sep;9(3):141–2.
10. Horn CC. Why is the neurobiology of nausea and vomiting so important? *Appetite*. 2008 Mar;50(2–3):430–4.
11. Benchoua HI, Siedek EM, De La Puente-Redondo VA, Tilt N, Rowan TG, Clemente RG. Efficacy of maropitant for preventing vomiting associated with motion sickness in dogs. *Vet Rec*. 2007 Sep 29;161(13):444–7.
12. Claude AK, Dedeeux A, Chiavaccini L, Hinz S. Effects of Maropitant Citrate or Acepromazine on the Incidence of Adverse Events Associated with Hydromorphone Premedication in Dogs. *J Vet Intern Med*. 2014 Sep;28(5):1414–7.
13. Kenward H, Elliott J, Lee T, Pelligand L. Anti-nausea effects and pharmacokinetics of ondansetron, maropitant and metoclopramide in a low-dose cisplatin model of nausea and vomiting in the dog: a blinded crossover study. *BMVC Vet Res*. 2017 Dec 16;13(1):244.
14. Koh RB, Isaza N, Xie H, Cooke K, Robertson SA. Effects of maropitant, acepromazine, and electroacupuncture on vomiting associated with administration of morphine in dogs. *J Am Vet Med Assoc*. 2014 Apr;244(7):820–9.
15. Kretzing S, Abraham G, Seiwert B, Ungemach FR, Krügel U, Teichert J, et al. In vivo assessment of antiemetic drugs and mechanism of lycorine-induced nausea and emesis. *Arch Toxicol*. 2011 Dec 31;85(12):1565–73.
16. Lorenzutti AM, Martin-Flores M, Litterio NJ, Himelfarb MA, Invalidi SH, Zarazaga MP. A comparison between maropitant and metoclopramide for the prevention of morphine-induced nausea and vomiting in dogs. *Can Vet J = La Rev Vet Can*. 2017 Jan;58(1):35–8.
17. Rau SE, Barber LG, Burgess KE. Efficacy of Maropitant in the Prevention of Delayed Vomiting Associated with Administration of Doxorubicin to Dogs. *J Vet Intern Med*. 2010 Nov;24(6):1452–7.
18. Swallow A, Rioja E, Elmer T, Dugdale A. The effect of maropitant on intraoperative isoflurane requirements and postoperative nausea and vomiting in dogs: a randomized clinical trial. *Vet Anaesth Analg*. 2017 Jul;44(4):785–93.
19. Jokar A, Khademhosseini P, Ahmadi K, Sistani A, Amiri M, Sinaki AG. A Comparison of Metoclopramide and Ondansetron Efficacy for the Prevention of Nausea and Vomiting In Patients Suffered From Renal Colic. *J Vet Intern Med*. 2017 Feb;31(1):36–43.
20. Arvasti K, Selianin-Toussi M, Hosseinzad-Ashkhi H, Shahidsales S. A Comparison of 5-HT3 Receptor Antagonist and Metoclopramide in the Patients Receiving Chemotherapeutic Regimens Including CMF, CAF and CHOP. *Iran J Cancer Prev*. 2015;8(2):84–8.
21. Singh P, Yoon SS, Koo B. Nausea: a review of pathophysiology and therapeutics. *Therap Adv Gastroenterol*. 2016;9:98–112.
22. Skalski A, Scalleld RD, Bailey AG. Practical selection of antiemetics. *Am Fam Physician*. 2004;69:1169–74.
23. Costall B, Naylor RJJ. Neuropharmacology of emesis in relation to clinical response. *Br J Cancer Suppl.* 1992;19:S2-7; discussion S7-8.
24. Ye J, H, Ponndurail R, Schaefer R. Ondansetron: A Selective 5-HT3 Receptor Antagonist and Its Applications in CNS-Related Disorders. *CNS Drug Rev*. 2006;7:199–213.
25. Wynn RL, Essien E, Thut PD. The effects of different antiemetic agents on morphine-induced emesis in ferrets. *Eur J Pharmacol*. 1993;241:47–54.
26. Quimby JM, Lake RC, Hansen RJ, et al. Oral, subcutaneous, and intravenous pharmacokinetics of ondansetron in healthy cats. *J Vet Pharmacol Ther*. 2014;37:348–53.
27. Elwood C, Devauchelle P, Elliott J, et al. Emesis in dogs: a review. *J Small Anim Pract*. 2010;51:4–22.
28. Balaban CD, Ogbum SW, Warshafsky SG, et al. Identification of Neural Networks That Contribute to Motion Sickness through Principal Components Analysis of Fos Labeling Induced by Galvanic Vestibular Stimulation. *PLoS One*. 2014;9:e86730.

29. Kenward H. Development of an objective means of assessing nausea in dogs. PhD-Thesis. London: EThOS British Library, 2015.

30. Ramsey L, eds. British Small Animal Veterinary Association Small animal formulary. Vol. 6. Hoboken: John Wiley & Sons, 2008.

31. Brandt T. Management of vestibular disorders. *J Neurol*. 2000;247:491–9.

32. Schunk KL. Disorders of the Vestibular System. *Vet Clin North Am Small Anim Pract*. 1988;18:641–65.

33. Morrow GR, Roscoe JA, Hickok JT, et al. Nausea and emesis: evidence for a biobehavioral perspective. *Support Care Cancer*. 2002;10:96–105.

34. Foubert J, Vaessen G. Nausea: the neglected symptom? *Eur J Oncol Nurs*. 2005;9:21–32.

35. Kraus BLH, Cazlan C. Assessment of Dog Owner Concern Regarding Peri-operative Nausea and Vomiting and Willingness to Pay for Anti-emetic Treatment. *Front Vet Sci*. 2019;6:1–9.

36. Bongartz U, Nessler J, Maiolini A, et al. Vestibular disease in dogs: association between neurological examination, MRI lesion localisation and outcome. *J Small Anim Pract*. 2020;61:57–63.

37. Orlandi R, Gutierrez-Quintana R, Carletti B, et al. Clinical signs, MRI findings and outcome in dogs with peripheral vestibular disease: a retrospective study. *BMC Vet Res*. 2020;16:159.

38. Fluehmann G, Doherr MG, Jaggy A. Canine neurological diseases in a referral hospital population between 1989 and 2000 in Switzerland. *J Small Anim Pract*. 2006;47:582–7.

39. Garosi LS, Dennis R, Penderis J, et al. Results of magnetic resonance imaging in dogs with vestibular disorders: 85 cases (1996-1999). *J Am Vet Med Assoc*. 2001;218:385–91.

40. Mayousse V, Desquilet L, Jeandel A, et al. Prevalence of neurological disorders in French bulldog: a retrospective study of 343 cases (2002–2016). *BMC Vet Res*. 2017;13:212.

41. Boudreau CE, Dominguez CE, Levine JM, et al. Reliability of interpretation of neurologic examination findings for the localization of vestibular dysfunction in dogs. *J Am Vet Med Assoc*. 2018;252:830–8.

42. Stern RM, Koch K, Andrews PLR. Nausea: Mechanisms and management. Oxford: Oxford University Press, 2011.

43. Gupta VK. Vasopressin: neurohumoral link between nausea and motion sickness. *Aviat Space Environ Med*. 2005;76:805.

44. Page SR, Peterson DB, Crosby SR, et al. The responses of arginine vasopressin and adrenocorticotrophin to nausea induced by ipecacuanha. *Clin Endocrinol (Oxf)*. 1990;33:761–70.

45. Otto B, Riepl RL, Klosterhalfen S, Enck P. Endocrine correlates of acute nausea and vomiting. *Auton Neurosci*. 2006;129:17–21.

46. Page H. Serotonin (5-Hydroxytryptamine). *Physiol Rev*. 1954;34:563–88.

47. Morales M, Battenberg E, Bloom FE. Distribution of Neurons Expressing Immunoreactivity for the 5HT3 Receptor Subtype in the Rat Brain and Spinal Cord. *J Comp Neurol*. 1999;406:141–141.

48. Tecott LH, Maricq AV, Julius D. Nervous system distribution of the serotonin 5-HT3 receptor mRNA. *Proc Natl Acad Sci*. 1993;90:1430–4.

49. Bradley PB, Engel G, Feniuk W, et al. Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine. *Neuropsychopharmacology*. 1986;25:563–76.

50. Kilpatrick GJ, Jones BJ, Tyers MB. The distribution of specific binding of the 5-HT3 receptor ligand [3H]GR65630 in rat brain using quantitative autoradiography. *Neurosci Lett*. 1988;94:141–141.

51. Pratt GD, Bowery NG, Kilpatrick GJ, et al. Consensus meeting agrees distribution of 5-HT3 receptors in mammalian hindbrain. *Trends Pharmacol Sci*. 1990;11:135–7.

52. Ohuoha DC, Knable MB, Wolf SS, et al. The subnuclear distribution of 5-HT3 receptors in the human nucleus of the solitary tract and other structures of the caudal medulla. *Brain Res*. 1994;637:222–6.

53. Reynolds DJM, Leslie RA, Grahame-Smith DG, et al. Localization of 5-HT3 receptor binding sites in human dorsal vagal complex. *Eur J Pharmacol*. 1989;174:127–30.

54. Miller AD, Rowley HA, Roberts TPL, Kucharczyk J. Human Cortical Activity during Vestibular- and Drug-Induced Nausea Detected Using MSI. *J Small Anim Pract*. 1996;781:670–2.

55. Sarla A. The tachykinin NK1 receptor in the brain: pharmacology and putative functions. *Eur J Pharmacol*. 1999;375:51–60.

56. Mansour A, Meadow-Woodruff JH, Bunzow JR, et al. Localization of dopamine D2 receptor mRNA and D1 and D2 receptor binding in the rat brain and pituitary: An in situ hybridization-receptor autoradiographic analysis. *J Neurosci*. 1990;10:2587–600.

57. Fox RA. Current status: animal models of nausea. In: Bianchi AL, Grélot L, Miller AD, King GL, eds. Mechanisms and Control of Emesis. France: John Libbey Eurotext, 1992: 341–50.

58. Meek R, Kelly A-M, Hu XF. Use of the visual analog scale to rate and monitor severity of nausea in the emergency department. *Acad Emerg Med*. 2009;16:1304–10.

59. Reid J, Nolan AM, Scott EM. Measuring pain in dogs and cats using structured behavioural observation. *Vet J*. 2018;236:72–9.

60. Downie WW, Leatham PA, Rhind VM, et al. Studies with pain rating scales. *Ann Rheum Dis*. 1978;37:378–81.

61. Holton LL, Scott EM, Nolan AM, et al. Relationship between physiological factors and clinical pain in dogs scored using a numerical rating scale. *J Small Anim Pract*. 1998;39:469–74.
62. de la Puente-Redondo VA, Tilt N, Rowan TG, et al. Efficacy of maropitant for treatment and prevention of emesis caused by intravenous infusion of cisplatin in dogs. *Am J Vet Res.* 2007;68:48–56.

63. Kim MS, Chey WD, Owyang C, et al. Role of plasma vasopressin as a mediator of nausea and gastric slow wave dysrhythmias in motion sickness. *Am J Physiol Liver Physiol.* 1997;272:G853–62.

64. Horii A, Kitahara T, Uno A, et al. Vestibular function and vasopressin. *Acta Otolaryngol.* 2004;124:50–3.

65. Farmer AD, Ban VF, Coen SJ, et al. Visually induced nausea causes characteristic changes in cerebral, autonomic and endocrine function in humans. *J Physiol.* 2015;593:1183–96.